Cyclosporine in severe childhood atopic dermatitis: a multicenter study

J Berth-Jones, A Y Finlay, I Zaki, B Tan, H Goodyear, S Lewis-Jones, M J Cork, S S Bleehen, M S Salek, B R Allen, S Smith, R A Graham-Brown

Research output: Contribution to journalArticlepeer-review

190 Citations (Scopus)


BACKGROUND: Severe atopic dermatitis (AD) remains difficult to treat. Cyclosporine is effective in adults but has not previously been investigated in children with AD.

OBJECTIVE: The aims were to investigate the efficacy, safety, and tolerability of cyclosporine in severe refractory childhood AD.

METHODS: Subjects 2 to 16 years of age were treated for 6 weeks with cyclosporine, 5 mg/kg per day, in an open study. Disease activity was monitored every 2 weeks by means of sign scores, visual analogue scales for symptoms, and quality-of-life questionnaires. Adverse events were monitored. Efficacy and tolerability were assessed with five-point scales.

RESULTS: Twenty-seven children were treated. Significant improvements were seen in all measures of disease activity. Twenty-two showed marked improvement or total clearing. Quality of life improved for both the children and their families. Tolerability was considered good or very good in 25 subjects.

CONCLUSION: Cyclosporine may offer an effective, safe, and well-tolerated short-term treatment option for children with severe AD.

Original languageEnglish
Pages (from-to)1016-21
Number of pages6
JournalJournal of the American Academy of Dermatology
Issue number6
Publication statusPublished - Jun 1996


  • Administration, Oral
  • Administration, Topical
  • Adolescent
  • Anti-Inflammatory Agents/therapeutic use
  • Capsules
  • Child
  • Child, Preschool
  • Cyclosporine/administration & dosage
  • Dermatitis, Atopic/drug therapy
  • Drug Tolerance
  • Female
  • Follow-Up Studies
  • Glucocorticoids
  • Humans
  • Immunosuppressive Agents/administration & dosage
  • Male
  • Quality of Life
  • Remission Induction
  • Safety
  • Solutions


Dive into the research topics of 'Cyclosporine in severe childhood atopic dermatitis: a multicenter study'. Together they form a unique fingerprint.

Cite this